

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 安 卓 健 有 限 公 司

TIAN AN MEDICARE LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

ANNOUNCEMENT MADE PURSUANT TO RULE 13.51B(2) OF THE LISTING RULES

This announcement is made by Tian An Medicare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to an update of information of Dr. Wong Wing Kuen, Albert (“**Dr. Wong**”), an independent non-executive director of the Company.

Reference is made to the announcement published by Dexin China Holdings Company Limited (stock code: 2019) (“**Dexin China**”) on 12 June 2024 (the “**Announcement**”) in relation to, among other things, the winding up order against Dexin China, an independent third party unrelated to the Group. According to the Announcement, Dexin China was ordered to be wound up by the High Court of The Hong Kong Special Administrative Region on 11 June 2024 and the Official Receiver was appointed as the provisional liquidator of Dexin China. Dr. Wong was an independent non-executive director of Dexin China immediately before the winding up order was granted against Dexin China.

For the avoidance of doubt, the Announcement relates to Dexin China only and does not involve any director (save for Dr. Wong) or senior management of the Company.

For further information regarding the winding-up of Dexin China, please refer to the respective announcements of Dexin China dated 21 March 2024, 5 June 2024 and 12 June 2024 published on the website of the Stock Exchange. Dr. Wong has confirmed that save as disclosed in this announcement, there are no other matters which are required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and he is not aware of any other matters that need to be brought to the attention of the Company and its shareholders.

The Board is of the view that the aforesaid matter does not have any impact on the business and operations of the Group, nor does it affect Dr. Wong's ability to discharge his duties as an independent non-executive director, the chairman of each of the audit committee and the environmental, social and governance committee and member of each of the remuneration committee and nomination committee of the Company.

By Order of the Board
Tian An Medicare Limited
Kong Muk Yin
Executive Director

Hong Kong, 18 June 2024

As at the date of this announcement, the Board comprises Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying being Executive Directors; Mr. Lee Seng Hui (Chairman), Mr. Mark Wong Tai Chun and Mr. Gao Zhaoyuan being Non-Executive Directors; and Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa being Independent Non-Executive Directors.